Exosomes at the crossroad between therapeutic targets and therapy resistance in head and neck squamous cell carcinoma

被引:13
作者
Jangholi, Abolfazl [1 ,2 ]
Bark, Juliana Muller [2 ]
Kenny, Lizbeth [3 ,4 ]
Vasani, Sarju [3 ,5 ]
Rao, Sudha [6 ]
Dolcetti, Riccardo [7 ,8 ,9 ,10 ]
Punyadeera, Chamindie [2 ,11 ]
机构
[1] Queensland Univ Technol, Ctr Biomed Technol, Sch Biomed Sci, Kelvin Grove, Qld, Australia
[2] Griffith Univ, Sch Environm & Sci, Griffith Inst Drug Discovery GRIDD, Brisbane, Qld, Australia
[3] Royal Brisbane & Womens Hosp, Canc Care Serv, Herston, Qld, Australia
[4] Univ Queensland, Fac Med, Brisbane, Qld, Australia
[5] Royal Brisbane & Womens Hosp, Dept Otolaryngol, Herston, Qld, Australia
[6] QIMR Berghofer Med Res Inst, Gene Regulat & Translat Med Lab, Brisbane, Qld, Australia
[7] Peter MacCallum Canc Ctr, Melbourne, Vic 3000, Australia
[8] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3010, Australia
[9] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia
[10] Univ Queensland, Diamantina Inst, Brisbane, Qld, Australia
[11] Griffith Univ, Menzies Hlth Inst Queensland MIHQ, Gold Coast, Australia
来源
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2022年 / 1877卷 / 05期
基金
英国医学研究理事会;
关键词
Head and neck cancer; HNSCC; Exosomes; Therapy resistance; Immune modulation; Drug delivery; Immunotherapy; Vaccines; EXTRACELLULAR VESICLES; TUMOR MICROENVIRONMENT; LIQUID BIOPSY; DENDRITIC CELLS; CANCER-THERAPY; PHASE-II; T-CELLS; BIOGENESIS; GROWTH; IMMUNOTHERAPY;
D O I
10.1016/j.bbcan.2022.188784
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Head and neck squamous cell carcinomas (HNSCCs) are aggressive and clinically challenging tumours that require a multidisciplinary management approach. Despite significant therapy improvements, HNSCC patients have a poor prognosis with a 5-year survival rate of about 65%. As recently recognised key players in cancer, exosomes are extracellular vesicles (EVs) with a diameter of nearly 50-120 nm which transport information from one cell to another. Exosomes are actively involved in various aspects of tumour initiation, development, metastasis, immune regulation, therapy resistance, and therapeutic applications. However, current knowledge of the role of exosomes in the pathophysiological processes of HNSCC is still in its infancy, and additional studies are needed. In this review, we summarise and discuss the relevance of exosomes in mediating local immuno-suppression and therapy resistance of HNSCC. We also review the most recent studies that have explored the therapeutic potential of exosomes as cancer vaccines, drug carriers or tools to reverse the drug resistance of HNSCC.
引用
收藏
页数:11
相关论文
共 161 条
[111]   Dendritic cell-derived exosomes may be a tool for cancer immunotherapy by converting tumor cells into immunogenic targets [J].
Romagnoli, Graziela Gorete ;
Zelante, Bruna Barbosa ;
Toniolo, Patricia Argenta ;
Migliori, Isabella Katz ;
Barbuto, Jose Alexandre M. .
FRONTIERS IN IMMUNOLOGY, 2015, 5
[112]   Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors [J].
Sacco, Assuntina G. ;
Worden, Francis P. .
ONCOTARGETS AND THERAPY, 2016, 9 :1927-1943
[113]   Subcellular targets of cisplatin cytotoxicity: An integrated view [J].
Sancho-Martinez, Sandra M. ;
Prieto-Garcia, Laura ;
Prieto, Marta ;
Lopez-Novoa, Jose M. ;
Lopez-Hernandez, Francisco J. .
PHARMACOLOGY & THERAPEUTICS, 2012, 136 (01) :35-55
[114]   The development of a liquid biopsy for head and neck cancers [J].
Schmidt, Henri ;
Kulasinghe, Arutha ;
Kenny, Liz ;
Punyadeera, Chamindie .
ORAL ONCOLOGY, 2016, 61 :8-11
[115]   Circulating Exosomes Inhibit B Cell Proliferation and Activity [J].
Schroeder, Jan C. ;
Puntigam, Lisa ;
Hofmann, Linda ;
Jeske, Sandra S. ;
Beccard, Inga J. ;
Doescher, Johannes ;
Laban, Simon ;
Hoffmann, Thomas K. ;
Brunner, Cornelia ;
Theodoraki, Marie-Nicole ;
Schuler, Patrick J. .
CANCERS, 2020, 12 (08) :1-16
[116]   Application of a Persistent Heparin Treatment Inhibits the Malignant Potential of Oral Squamous Carcinoma Cells Induced by Tumor Cell-Derived Exosomes [J].
Sento, Shinya ;
Sasabe, Eri ;
Yamamoto, Tetsuya .
PLOS ONE, 2016, 11 (02)
[117]   Activated CD8+ T cell extracellular vesicles prevent tumour progression by targeting of lesional mesenchymal cells [J].
Seo, Naohiro ;
Shirakura, Yoshitaka ;
Tahara, Yoshiro ;
Momose, Fumiyasu ;
Harada, Naozumi ;
Ikeda, Hiroaki ;
Akiyoshi, Kazunari ;
Shiku, Hiroshi .
NATURE COMMUNICATIONS, 2018, 9
[118]   Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group study [J].
Siu, Lillian L. ;
Soulieres, Denis ;
Chen, Eric X. ;
Pond, Gregory R. ;
Chin, Soo F. ;
Francis, Peggy ;
Harvey, Luc ;
Klein, Meri ;
Zhang, Wenjiang ;
Dancey, Janet ;
Eisenhauer, Elizabeth A. ;
Winquist, Eric .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (16) :2178-2183
[119]   The role of tumor microenvironment in therapeutic resistance [J].
Son, Beomseok ;
Lee, Sungmin ;
Youn, HyeSook ;
Kim, EunGi ;
Kim, Wanyeon ;
Youn, BuHyun .
ONCOTARGET, 2017, 8 (03) :3933-3945
[120]   Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck [J].
Soulieres, D ;
Senzer, NN ;
Vokes, EE ;
Hidalgo, M ;
Agarwala, SS ;
Siu, LL .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :77-85